A5036850777- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Glycosylation and Glycoproteins Research
- Acute Myeloid Leukemia Research
- RNA and protein synthesis mechanisms
- Advanced Biosensing Techniques and Applications
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Toxin Mechanisms and Immunotoxins
- Fungal Infections and Studies
- Advanced biosensing and bioanalysis techniques
- CNS Lymphoma Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Hematopoietic Stem Cell Transplantation
- HIV Research and Treatment
- Colorectal Cancer Treatments and Studies
University of Cologne
2004-2019
University Hospital Cologne
2005-2015
German Inflammatory Bowel Diseases Study Group
2013-2014
Health First
2014
University of Verona
2011
City of Hope
2011
Commonwealth Scientific and Industrial Research Organisation
2005-2008
Natural killer (NK) cells represent a key component of the innate immune system against cancer. Nevertheless, malignant diseases arise in immunocompetent individuals despite tumor immunosurveillance. Hodgkin lymphoma (HL) is characterized by CD30(+) and massive infiltration effector affected lymph nodes. The latter obviously fail to eliminate cell population. Here, we tested for functional NK defects HL suggest an improvement function therapeutic means. We demonstrate that peripheral (pNK)...
Purpose Older patients with Hodgkin lymphoma (HL) account for approximately 20% of all HL patients. ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard care in these However, little known on feasibility efficacy this age group. Patients Methods We analyzed the four cycles older 60 to 75 years early-stage who were treated within German Study Group (GHSG) HD10 HD11 trials; results compared those younger trials. Results In total, 1,299 received ABVD,...
While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few available about the prognostic impact, predictive value for different treatments, and genetic heterogeneity of ROS1-positive patients.1137 adenocarcinoma lung were analyzed regarding their status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments outcome these assessed. Overall survival (OS) compared genetically defined subgroups...
Display technologies are fundamental to the isolation of specific high-affinity binding proteins for diagnostic and therapeutic applications in cancer, neurodegenerative, infectious diseases as well autoimmune inflammatory disorders. Applications extend into broad field antibody (Ab) engineering, synthetic enzymes, proteomics, cell-free protein synthesis. Recently, vitro display have come prominence due human antibodies by phage display, development novel scaffolds ribosome discovery...
NKG2D, an activating receptor expressed on NK cells and T cells, is critically involved in tumor immunosurveillance. In this study, we explored the potential therapeutic utility of NKG2D ligand ULBP2 for treatment colon carcinoma. To end designed a fusion protein consisting human antibody-derived single chain targeting carcinoembryonic antigen (CEA). The bispecific recombinant re-directed towards malignant by binding to both, triggered cell-mediated target cell killing vitro. Moreover,...
Progress in recent years strengthened the concept of cellular tumor vaccinations. However, a crucial barrier to successful cancer immunotherapy is tumor-mediated immunosuppression. Tumor-derived soluble factors such as IL-10, TGF-β, and VEGF suppress effector cells either directly or indirectly by disruption dendritic cell (DC) differentiation, migration antigen presentation. Human B acquire potent immunostimulatory properties when activated via CD40 have been shown be an alternative source...
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients with Hodgkin lymphoma (HL). We thus retrospectively analyzed 14 primary HL who were treated as single agent a named patient program, had not received prior high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) due to disease (n = 9), comorbidity 4) unknown reasons 1). Brentuximab resulted an overall response rate 71% (10/14) five complete...
Targeted treatment of non-small cell lung cancer (NSCLC) with driver aberrations has drastically improved the outcome a subset patients. However, for successful adaptation in clinical routine, many stakeholders are involved, like comprehensive centers, molecular pathology, peripheral hospitals, and oncology practices. Here, we present single center experience personalized Germany. Patients advanced NSCLC need systemic after identification targetable mutation have been included this analysis....
e20541 Background: Neurotrophic receptor tyrosine kinase (NTRK) fusions occur in less than 1% non-small cell lung cancer (NSCLC) cases and have been the focus of recent therapeutic advances. However, role NTRK1-3 point mutations NSCLC remains unexplored. Molecular analyses were performed a cohort patients with to elucidate their clinical relevance. Methods: data collected analyzed from Network Genomic Medicine (NGM) database Germany between 2022 2024. Mutations identified by next-generation...
Abstract Cancer that might develop as host natural killer (NK) cells fail to detect ligands for their activating NK receptors. Immunoligands represent promising immunotherapeutic tools overcome this deficit. These are fusion proteins containing a single-chain antibody fragment (scFv) target an available tumor antigen and ULBP2 activate by targeting the activatory receptor NKG2D. Prostate-specific membrane (PSMA) is integral non-shed type 2 protein highly specifically expressed on prostate...
Due to its selective overexpression on the malignant cells of Hodgkin's lymphoma (HL) and large cell anaplastic (ALCL), CD30 is an excellent target for immunotherapy these diseases. The fully human monoclonal anti-CD30-antibody 5F11 has been shown be effective against CD30-expressing lines both in vitro vivo. In addition, shows promising antitumor activity phase 1/2 clinical trials. To extend results, authors evaluated combinations with conventional cytostatic drugs a variety vitro. Most...